- Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
-
Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon
-
J Mov Disord. 2018;11(2):65-71. Published online May 30, 2018
-
DOI: https://doi.org/10.14802/jmd.18005
-
-
8,664
View
-
246
Download
-
14
Citations
-
 Abstract
 PDF Supplementary Material
- Objective
We examined whether amantadine can prevent the development of dyskinesia.
Methods
Patients with drug-naïve Parkinson’s disease (PD), younger than 70 years of age and in the early stage of PD (Hoehn and Yahr scale < 3), were recruited from April 2011 to December 2014. The exclusion criteria included the previous use of antiparkinsonian medication, the presence of dyskinesia, significant psychological disorders, and previous history of a hypersensitivity reaction. Patients were consecutively assigned to one of 3 treatment groups in an open label fashion: Group A-1, amantadine first and then levodopa when needed; Group A-2, amantadine first, dopamine agonist when needed, and then levodopa; and Group B, dopamine agonist first and then levodopa when needed. The primary endpoint was the development of dyskinesia, which was analyzed by the Kaplan-Meier survival rate.
Results
A total of 80 patients were enrolled: Group A-1 (n = 27), Group A-2 (n = 27), and Group B (n = 26). Twenty-four patients were excluded from the analysis due to the following: withdrawal of amantadine or dopamine agonist (n = 9), alternative diagnosis (n = 2), withdrawal of consent (n = 1), and breach in the protocol (n = 12). After exclusion, 5 of the 56 (8.93%) patients developed dyskinesia. Patients in Group A-1 and A-2 tended to develop dyskinesia less often than those in Group B (cumulative survival rates of 0.933, 0.929, and 0.700 for A-1, A-2, and B, respectively; p = 0.453).
Conclusion
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.
-
Citations
Citations to this article as recorded by  - Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon
Journal of Movement Disorders.2023; 16(2): 224. CrossRef - Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung
J. Bedarf, I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
DGNeurologie.2023; 6(6): 504. CrossRef - Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem
Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov
Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(1): 17. CrossRef - Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
Imane Frouni, Woojin Kang, Dominique Bédard, Sébastien Belliveau, Cynthia Kwan, Shadi Hadj-Youssef, Élodie Bourgeois-Cayer, Leanne Ohlund, Lekha Sleno, Adjia Hamadjida, Philippe Huot
European Journal of Pharmacology.2022; 929: 175090. CrossRef - Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19
E.A. Katunina
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101. CrossRef - Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska
Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef - Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets
Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang
Journal of Neuroscience Research.2020; 98(1): 19. CrossRef - Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Expert Opinion on Emerging Drugs.2020; 25(2): 131. CrossRef - Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD)
Michelle Ann C. Sy, Hubert H. Fernandez
Neurotherapeutics.2020; 17(4): 1331. CrossRef - Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Jing Liu, Fei Xu, Zhiyan Nie, Lei Shao
Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef - Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
Susan H. Fox, Jonathan M. Brotchie
European Journal of Neuroscience.2019; 49(3): 399. CrossRef - Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
Journal of Neural Transmission.2019; 126(7): 871. CrossRef - Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot
Neuropharmacology.2019; 158: 107725. CrossRef - Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
Valentina Leta, Peter Jenner, K. Ray Chaudhuri, Angelo Antonini
Expert Opinion on Drug Safety.2019; 18(12): 1203. CrossRef
- Myotonia Congenita Can Be Mistaken as Paroxysmal Kinesigenic Dyskinesia
-
Aryun Kim, Mihee Jang, Han-Joon Kim, Yoon Kim, Dae-Seong Kim, Jin-Hong Shin, Beomseok Jeon
-
J Mov Disord. 2018;11(1):49-51. Published online January 23, 2018
-
DOI: https://doi.org/10.14802/jmd.17056
-
-
7,043
View
-
128
Download
-
4
Citations
-
PDF
-
Citations
Citations to this article as recorded by - Genetic updates on paroxysmal dyskinesias
James Y. Liao, Philippe A. Salles, Umar A. Shuaib, Hubert H. Fernandez
Journal of Neural Transmission.2021; 128(4): 447. CrossRef - A Japanese family with primary familial brain calcification presenting with paroxysmal kinesigenic dyskinesia - A comprehensive mutational analysis-
Akihiko Mitsutake, Takashi Matsukawa, Kristine Joyce L. Porto, Tatsuya Sato, Junko Katsumata, Tomonari Seki, Risa Maekawa, Takuto Hideyama, Masaki Tanaka, Hiroyuki Ishiura, Tatsushi Toda, Shoji Tsuji, Yasushi Shiio
Journal of the Neurological Sciences.2020; 418: 117091. CrossRef - Paroxysmal movement disorders – practical update on diagnosis and management
Claudio M. De Gusmao, Laura Silveira-Moriyama
Expert Review of Neurotherapeutics.2019; 19(9): 807. CrossRef - The study of exercise tests in paroxysmal kinesigenic dyskinesia
Hai-Yan Zhou, Fei-Xia Zhan, Wo-Tu Tian, Chao Zhang, Yan Wang, Ze-Yu Zhu, Xiao-Li Liu, Yang-Qi Xu, Xing-Hua Luan, Xiao-Jun Huang, Sheng-Di Chen, Li Cao
Clinical Neurophysiology.2018; 129(11): 2435. CrossRef
- Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson’s Disease
-
Ryul Kim, Han-Joon Kim, Aryun Kim, Mi-Hee Jang, Hyun Jeong Kim, Beomseok Jeon
-
J Mov Disord. 2018;11(1):30-34. Published online January 11, 2018
-
DOI: https://doi.org/10.14802/jmd.17038
-
-
8,571
View
-
239
Download
-
14
Citations
-
Abstract
PDF
- Objective
Two conversion tables between the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have recently been established for Parkinson’s disease (PD). This study aimed to validate them in Korean patients with PD and to evaluate whether they could be influenced by educational level.
Methods
A total of 391 patients with PD who undertook both the Korean MMSE and the Korean MoCA during the same session were retrospectively assessed. The mean, median, and root mean squared error (RMSE) of the difference between the true and converted MMSE scores and the intraclass correlation coefficient (ICC) were calculated according to educational level (6 or fewer years, 7–12 years, or 13 or more years).
Results
Both conversions had a median value of 0, with a small mean and RMSE of differences, and a high correlation between the true and converted MMSE scores. In the classification according to educational level, all groups had roughly similar values of the median, mean, RMSE, and ICC both within and between the conversions.
Conclusion
Our findings suggest that both MMSE-MoCA conversion tables are useful instruments for transforming MoCA scores into converted MMSE scores in Korean patients with PD, regardless of educational level. These will greatly enhance the utility of the existing cognitive data from the Korean PD population in clinical and research settings.
-
Citations
Citations to this article as recorded by - Gaze Scanning at Street Crossings by Pedestrians With Homonymous Hemianopia With and Without Hemispatial Neglect
Shrinivas Pundlik, Matteo Tomasi, Kevin E. Houston, Ayush Kumar, Prerana Shivshanker, Alex R. Bowers, Eli Peli, Gang Luo
Investigative Opthalmology & Visual Science.2023; 64(14): 26. CrossRef - Comparative study of two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive Impairment
Yu-Yuan Huang, Shu-Xia Qian, Qiao-Bing Guan, Ke-Liang Chen, Qian-Hua Zhao, Jia-Hong Lu, Qi-Hao Guo
Applied Neuropsychology: Adult.2021; 28(1): 88. CrossRef - Conversion between Mini‐Mental State Examination and Montreal Cognitive Assessment scores in older adults undergoing selective surgery using Rasch analysis
Xiaoying Chen, Huangliang Wen, Jinni Wang, Yayan Yi, Jialan Wu, Xiaoyan Liao
Journal of Advanced Nursing.2021; 77(2): 729. CrossRef - Converting from the Montreal Cognitive Assessment to the Mini-Mental State Examination-2
Hwabeen Yang, Daehyuk Yim, Moon Ho Park, Antony Bayer
PLOS ONE.2021; 16(7): e0254055. CrossRef - Validation of Four Methods for Converting Scores on the Montreal Cognitive Assessment to Scores on the Mini-Mental State Examination-2
Sung Hoon Kang, Moon Ho Park
Dementia and Neurocognitive Disorders.2021; 20(4): 41. CrossRef - Կոգնիտիվ վիճակի գնահատման Mini-Mental State Examination (MMSE) սանդղակի հայերեն տարբերակի ադապտացում և վալիդացում
Մ.Ա. Իսայան, Հ.Ա. Հովակիմյան, Լ.Վ. Վարդանյան, Ս.Գ. Խաչատրյան, Զ.Դ. Թավադյան
Armenian Journal of Health & Medical Sciences.2021; : 27. CrossRef - Determinant of Quality of Life in Patients with Chronic Cerebral Infarct
Yujin Lee, Joon Sung Kim, Bo Young Hong, Jung Geun Park, Jae Wan Yoo, Kyoung Bo Lee, Tae-Woo Kim, Seong Hoon Lim
Brain & Neurorehabilitation.2020;[Epub] CrossRef - Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease
Jannik Florian Scheffels, Leon Fröhlich, Elke Kalbe, Josef Kessler
Journal of the Neurological Sciences.2020; 412: 116735. CrossRef - Hand motor functions on the presence of red fluorescent dental biofilm in older community-dwelling Koreans
Na-Ri Shin, Yeo-Jin Yi, Jun-Seon Choi
Photodiagnosis and Photodynamic Therapy.2019; 28: 120. CrossRef - Is the modified Mann Assessment of Swallowing Ability useful for assessing dysphagia in patients with mild to moderate dementia?
Eun Kyu Ji, Hae Hyun Wang, Sung June Jung, Kyoung Bo Lee, Joon Sung Kim, Bo Young Hong, Seong Hoon Lim
Journal of Clinical Neuroscience.2019; 70: 169. CrossRef - The Changes for Strength of Oropharyngeal Muscles in Patients with Dementia and Dysphagia
Eun Kyu Ji, Hae Hyun Wang, Sung June Jung, Kyoung Bo Lee, Joon Sung Kim, Bo Young Hong, Tae-Woo Kim, Seong Hoon Lim
Brain & Neurorehabilitation.2019;[Epub] CrossRef - Konversionen von kognitiven Screenings
J. F. Scheffels, H. Kräling, E. Kalbe, J. Kessler
Der Nervenarzt.2018; 89(12): 1371. CrossRef - Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline
Loic Carment, Abir Abdellatif, Carmelo Lafuente-Lafuente, Sylvie Pariel, Marc A. Maier, Joël Belmin, Påvel G. Lindberg
Frontiers in Neurology.2018;[Epub] CrossRef - Validation of MoCA-MMSE Conversion Scales in Korean Patients with Cognitive Impairments
Young Ik Jung, Eun Hye Jeong, Heejin Lee, Junghee Seo, Hyun-Jeong Yu, Jin Y. Hong, Mun Kyung Sunwoo
Dementia and Neurocognitive Disorders.2018; 17(4): 148. CrossRef
- Need for Registration and Reporting of Acupuncture Trials in Parkinson’s Disease in Korea
-
Timothy E. Lee, Aryun Kim, Mihee Jang, Beomseok Jeon
-
J Mov Disord. 2017;10(3):130-134. Published online September 22, 2017
-
DOI: https://doi.org/10.14802/jmd.17047
-
-
Abstract
PDF
- Objective
Many people dealing with Parkinson’s disease (PD) turn to complementary and alternative medicine when searching for a cure or relief from symptoms. Acupuncture is widely used in the Korean PD population to alleviate symptoms and in hopes of curing the illness. However, acupuncture use for PD patients has only recently begun to be studied scientifically and is still considered an unproven treatment for PD. Therefore, there is an urgent need for acupuncture to be studied, validated and used for PD. Thus, our study’s aim is to examine how many acupuncture studies in PD are registered and reported in Korea.
Methods
The registries Clinicaltrials.gov and the Clinical Research Information Service (CRIS) and the search engine PubMed were searched to find relevant human clinical studies involving acupuncture therapy in PD patients. We examined the registration of trials, the posting and publication of results, and whether published articles were registered.
Results
In Clinicaltrials.gov, one completed trial was found with published results. In CRIS, one completed trial was found with published results. A total of 6 publications were found in our study: 2 articles were registered, but only 1 had the registered trial number listed in the article.
Conclusion
Acupuncture is popular among the PD population in Korea regardless of its unproven safety and efficacy. Despite the pressing need for clinical trials, the number of studies listed in the registries was small, and only a few publications were registered. More effort and rigor are needed to validate the efficacy and safety of acupuncture for PD.
- A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease
-
Jae Young Joo, Ji Young Yun, Young Eun Kim, Yu Jin Jung, Ryul Kim, Hui-Jun Yang, Woong-Woo Lee, Aryun Kim, Han-Joon Kim
-
Received July 12, 2023 Accepted August 21, 2023 Published online August 22, 2023
-
DOI: https://doi.org/10.14802/jmd.23130
[Epub ahead of print]
-
-
Abstract
PDFSupplementary Material
- Objective
Parkinson’s disease (PD) patients often find it difficult to visit hospitals because of motor symptoms, distance to the hospital, or the absence of caregivers. Telemedicine is one way to solve this problem.
Methods
We surveyed 554 PD patients from eight university hospitals in Korea. The questionnaire consisted of the clinical characteristics of the participants, possible teleconferencing methods, and preferences for telemedicine.
Results
A total of 385 patients (70%) expressed interest in receiving telemedicine. Among them, 174 preferred telemedicine whereas 211 preferred in-person visits. The longer the duration of disease, and the longer the time required to visit the hospital, the more patients were interested in receiving telemedicine.
Conclusion
This is the first study on PD patients’ preferences regarding telemedicine in Korea. Although the majority of patients with PD have a positive view of telemedicine, their interest in receiving telemedicine depends on their different circumstances.
|
KMDS
E-submission
